Eli Lilly (LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that ...
"Lilly's next generation subcutaneous obesity treatment seems to be future proofing the company's weight management franchise," argued SA analyst BioCGT Investor. BioCGT expects the company to ...
2monon MSN
Eli Lilly (NYSE:LLY) is scheduled to announce Q3 ... LLY is up 55.6% so far this year and is rated as Hold according to SA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback